Olędzki Olędzki

Dr. Olędzki Olędzki


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2019 in Polish Heart Journal
Verified
Journal Article
Closed access
EPEdyta Płońska-Gościniak
Edyta Płońska-Gościniak
OOOlędzki Olędzki
Olędzki Olędzki
TKTomasz Kukulski
Tomasz Kukulski
WKWojciech Kosmala
Wojciech Kosmala
AMAgnieszka Mlynarska
Agnieszka Mlynarska
JKJarosław D. Kasprzak
Jarosław D. Kasprzak
BACKGROUND The rate of cardiac device-related infective endocarditis (CDRIE) is increasing worldwide, but no detailed data are available for Poland. AIMS We aimed to evaluate clinical, diagnostic, and therapeutic data of patients hospitalized due to CDRIE in 22 Polish referential cardiology centers from May 1, 2016 to May 1, 2017. METHODS Participating cardiology departments were asked to fill in a questionnaire that included data on the number of hospitalized patients, number and types of implanted cardiac electrotherapy devices, and number of infective endocarditis cases. We also collected clinical data and data regarding the management of patients with CDRIE. RESULTS Overall, 99621 hospitalizations were reported. Infective endocarditis unrelated to cardiac device was the cause of 596 admissions (0.6%), and CDRIE, of 195 (0.2%). Pacemaker was implanted in 91 patients with CDRIE (47%); cardioverter-defibrillator, in 51 (26%); cardiac resynchronization therapy-defibrillator, in 48 (25%); and cardiac resynchronization therapy-pacemaker, in 5 (2.5%). The most common symptoms were malaise (62%), fever/chills (61%), cough (21%), chest pain (19.5%), and inflammation of the device pocket (5.6%). Cultures were positive in 77.5% of patients. The cardiac device was removed in 91% of patients. The percutaneous approach was most common for cardiac device removal. All patients received antibiotic therapy, and 3 patients underwent a heart valve procedure. Transesophageal echocardiography was performed in 80% of patients. The most common complication was heart failure (25% of patients). CONCLUSIONS The clinical profile, pathogen types, and management strategies in Polish patients with CDRIE are consistent with similar data from other European countries. Transesophageal echocardiography was performed less frequently than recommended. The removal rate in the Polish population is consistent with the general rates observed for interventional treatment in patients with CDRIE.

8 September 2017 in Polish Heart Journal
Verified
Journal Article
Open access
PDF file
EPEdyta Płońska-Gościniak
Edyta Płońska-Gościniak
JKJarosław D. Kasprzak
Jarosław D. Kasprzak
OOOlędzki Olędzki
Olędzki Olędzki
JRJolanta Rzucidło-Resil
Jolanta Rzucidło-Resil
PGPiotr Gościniak
Piotr Gościniak
ZGZbigniew Gąsior
Zbigniew Gąsior
Background: Stress echocardiography (SE) is widely used in Europe. No collective data have been available on the use of SE in Poland until now. Aim: To evaluate the number of SE investigations performed in Poland, their settings, complications and results. Methods: In this retrospective survey, referral cardiology centers in Poland were asked to fill in a questionnaire regarding SE examinations performed from May 01, 2014 to May 01, 2015. Results: The study included data from 17 university hospitals and large community hospitals which performed 4611 SE examinations, including 4408 tests in patients investigated for coronary artery disease (CAD) and 203 tests to evaluate valvular heart disease (VHD). To evaluate CAD, all centers performed dobutamine SE (100%), 10 centers performed pacing SE (58.8%), while cycle ergometer SE and treadmill SE were performed by 6 (35.3%) and 5 (29.4%) centers, respectively. Dipyridamole SE was performed in one center. All evaluated centers (100%) performed SE to evaluate low-flow/low-gradient aortic stenosis (LFLG-AS), eight (47%) performed SE to evaluate asymptomatic aortic stenosis, and also eight (47%) performed SE to evaluate mitral regurgitation. The mean number of examinations per year was 271 per center. Most centers performed more than 100 examinations per year (11 centers, 64.7%). We did not identify any cardiac death during SE examination in any of the centers. Myocardial infarction occurred in 3 (0.07%) patients. Nonsustained ventricular tachycardia occurred in 52 (1.1%) SE examinations. The rates of minor complications were low. SE to evaluate CAD was more commonly performed in hospital settings using cycle ergometer (72.6%), treadmill (87.6%), and low-dose dobutamine (68.0%), while a dipyridamole test was more frequently employed in ambulatory patients (77.6%). No significant differences between the rates of examinations performed in ambulatory and hospital settings were found for high-dose dobutamine and pacing SE. Examinations to evaluate VHD were significantly more frequently performed in hospital settings. SE examinations amounted to more than one third of all stress tests performed in the surveyed centers over the study period. Conclusions: SE is a safe diagnostic method, and major complications are very rare. Despite European recommendations, SE examinations to evaluate CAD are performed less frequently than electrocardiographic exercise tests, although they already comprise a significant proportion of all stress tests. It seems reasonable to promote SE further for the evaluation of both CAD and VHD. Background: Stress echocardiography (SE) is widely used in Europe. No collective data have been available on the use of SE in Poland until now. Aim: To evaluate the number of SE investigations performed in Poland, their settings, complications and results. Methods: In this retrospective survey, referral cardiology centers in Poland were asked to fill in a questionnaire regarding SE examinations performed from May 01, 2014 to May 01, 2015. Results: The study included data from 17 university hospitals and large community hospitals which performed 4611 SE examinations, including 4408 tests in patients investigated for coronary artery disease (CAD) and 203 tests to evaluate valvular heart disease (VHD). To evaluate CAD, all centers performed dobutamine SE (100%), 10 centers performed pacing SE (58.8%), while cycle ergometer SE and treadmill SE were performed by 6 (35.3%) and 5 (29.4%) centers, respectively. Dipyridamole SE was performed in one center. All evaluated centers (100%) performed SE to evaluate low-flow/low-gradient aortic stenosis (LFLG-AS), eight (47%) performed SE to evaluate asymptomatic aortic stenosis, and also eight (47%) performed SE to evaluate mitral regurgitation. The mean number of examinations per year was 271 per center. Most centers performed more than 100 examinations per year (11 centers, 64.7%). We did not identify any cardiac death during SE examination in any of the centers. Myocardial infarction occurred in 3 (0.07%) patients. Nonsustained ventricular tachycardia occurred in 52 (1.1%) SE examinations. The rates of minor complications were low. SE to evaluate CAD was more commonly performed in hospital settings using cycle ergometer (72.6%), treadmill (87.6%), and low-dose dobutamine (68.0%), while a dipyridamole test was more frequently employed in ambulatory patients (77.6%). No significant differences between the rates of examinations performed in ambulatory and hospital settings were found for high-dose dobutamine and pacing SE. Examinations to evaluate VHD were significantly more frequently performed in hospital settings. SE examinations amounted to more than one third of all stress tests performed in the surveyed centers over the study period. Conclusions: SE is a safe diagnostic method, and major complications are very rare. Despite European recommendations, SE examinations to evaluate CAD are performed less frequently than electrocardiographic exercise tests, although they already comprise a significant proportion of all stress tests. It seems reasonable to promote SE further for the evaluation of both CAD and VHD.

6 June 2017 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
OOOlędzki Olędzki
Olędzki Olędzki
ZKZdzisława Kornacewicz-Jach
Zdzisława Kornacewicz-Jach
KSKrzysztof Safranow
Krzysztof Safranow
RKRadosław Kiedrowicz
Radosław Kiedrowicz
BGBarbara Gawrońska-Szklarz
Barbara Gawrońska-Szklarz
JGJarosław Gorący
Jarosław Gorący

31 January 2024 in Polish Heart Journal
Verified
Journal Article
Open access
PDF file
JPJerzy Pacholewicz
Jerzy Pacholewicz
AŻAndrzej Żych
Andrzej Żych
OOOlędzki Olędzki
Olędzki Olędzki
EPEdyta Płońska-Gościniak
Edyta Płońska-Gościniak

21 April 2017 in Annals of Noninvasive Electrocardiology
Verified
Journal Article
Closed access
PDF file
OOOlędzki Olędzki
Olędzki Olędzki
AWAndrzej Wojtarowicz
Andrzej Wojtarowicz
EPEdyta Płońska‐Gościniak
Edyta Płońska‐Gościniak
MLMaciej Lewandowski
Maciej Lewandowski
JGJarosław Gorący
Jarosław Gorący

3 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
OOOlędzki Olędzki
Olędzki Olędzki
Arnold KukowkaArnold Kukowka
Arnold Kukowka
ASAldona Siennicka
Aldona Siennicka
NJNatalia Jakubiak
Natalia Jakubiak
Dominika Maciejewska-MarkiewiczDominika Maciejewska-Markiewicz
Dominika Maciejewska-Markiewicz
JKJarosław Kaźmierczak
Jarosław Kaźmierczak
Background: Atherosclerosis is the main cause of coronary heart disease, which frequently precedes the onset of heart failure. Lipopolysaccharide (LPS), a pro-inflammatory endotoxin produced by Gram-negative bacteria, exacerbates atherosclerotic processes and negatively impacts myocardial function, particularly in the context of activating low grade inflammation. Zonulin, a key regulator of the blood-gut barrier, modulates tight junction permeability, potentially facilitating the translocation of microbial-derived compounds, including LPS, into the circulation. Given these interactions, we investigated serum levels of lipopolysaccharide and zonulin in patients following myocardial infarction. This study aimed to assess serum levels of zonulin and lipopolysaccharide (LPS) in patients who had experienced a myocardial infarction (MI) and to evaluate the association between these biomarkers and ejection fraction (EF) across different patient groups. Methods: 78 patients (22 women and 56 men) diagnosed with MI, who underwent primary PCI (percutaneous coronary intervention), were included in the study. The blood samples were collected between 24 and 48 h after PCI. Results: Post-myocardial infarction patients with an ejection fraction ≤ 40% exhibited significantly elevated serum lipopolysaccharide levels compared to those with an ejection fraction > 40%. However, no significant differences in zonulin levels were observed between the study groups. Conclusions: Our findings suggest that elevated serum lipopolysaccharide levels may be associated with a reduction in post-infarction ejection fraction. This observation highlights a potential link between endotoxemia and impaired myocardial function following MI, warranting further investigation.